Skip to main content Back to Top
Advertisement

10/9/2024

Lanreotide Acetate Injection

Products Affected - Description

    • Lanreotide Acetate subcutaneous injection, Cipla USA, 120 mg/0.5 mL, prefilled syringe, NDC 69097-0870-67
    • Lanreotide Acetate subcutaneous injection, Exelan Pharmaceuticals, 120 mg/0.5 mL, prefilled syringe, NDC 76282-0720-67

Reason for the Shortage

    • Cipla did not provide a reason for the shortage.
    • Exelan did not provide a reason for the shortage.
    • Ipsen Biopharmaceuticals has Somatuline Depot available.

Available Products

    • Somatuline Depot subcutaneous injection, Ipsen Biopharmaceuticals, 120 mg/0.5 mL, prefilled syringe, NDC 15054-1120-04
    • Somatuline Depot subcutaneous injection, Ipsen Biopharmaceuticals, 60 mg/0.2 mL, prefilled syringe, NDC 15054-1060-04
    • Somatuline Depot subcutaneous injection, Ipsen Biopharmaceuticals, 90 mg/0.3 mL, prefilled syringe, NDC 15054-1090-04

Estimated Resupply Dates

    • Cipla has lanreotide 120 mg/0.5 mL prefilled syringes on intermittent back order and the company is releasing supplies as they become available.
    • Exelan has lanreotide 120 mg/0.5 mL prefilled syringes on back order and the company cannot estimate a release date.

Updated

Created October 9, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT